- Home
- RARE vs XRAY Comparison
RARE vs XRAY Comparison
Compare RARE & XRAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- XRAY
- Stock Information
- Founded
- RARE 2010
- XRAY 1899
- Country
- RARE United States
- XRAY United States
- Employees
- RARE N/A
- XRAY N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- XRAY Medical/Dental Instruments
- Sector
- RARE Health Care
- XRAY Health Care
- Exchange
- RARE Nasdaq
- XRAY Nasdaq
- Market Cap
- RARE 3.6B
- XRAY 3.1B
- IPO Year
- RARE 2014
- XRAY 1987
- Fundamental
- Price
- RARE $33.84
- XRAY $14.65
- Analyst Decision
- RARE Strong Buy
- XRAY Hold
- Analyst Count
- RARE 15
- XRAY 13
- Target Price
- RARE $95.93
- XRAY $23.36
- AVG Volume (30 Days)
- RARE 748.6K
- XRAY 3.3M
- Earning Date
- RARE 05-01-2025
- XRAY 05-01-2025
- Dividend Yield
- RARE N/A
- XRAY 4.36%
- EPS Growth
- RARE N/A
- XRAY N/A
- EPS
- RARE N/A
- XRAY N/A
- Revenue
- RARE $560,230,000.00
- XRAY $3,793,000,000.00
- Revenue This Year
- RARE $19.15
- XRAY N/A
- Revenue Next Year
- RARE $32.11
- XRAY $2.56
- P/E Ratio
- RARE N/A
- XRAY N/A
- Revenue Growth
- RARE 29.01
- XRAY N/A
- 52 Week Low
- RARE $33.69
- XRAY $14.61
- 52 Week High
- RARE $60.37
- XRAY $33.02
- Technical
- Relative Strength Index (RSI)
- RARE 27.75
- XRAY 27.95
- Support Level
- RARE $36.71
- XRAY $14.61
- Resistance Level
- RARE $39.21
- XRAY $16.02
- Average True Range (ATR)
- RARE 1.34
- XRAY 0.46
- MACD
- RARE -0.32
- XRAY 0.02
- Stochastic Oscillator
- RARE 2.19
- XRAY 2.84
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About XRAY DENTSPLY SIRONA Inc.
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (manufactured dental consumables and lab products) and Sirona Dental Systems (manufactured technologically-advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology and equipment through third-party distributors and the remaining portfolio is either sold to labs and offices through the firm's salesforce or directly to consumers (such as Byte clear aligner).